

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	26 March 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	(a) 30 April 2019 (b) 30 April 2019 (c) 2 May 2019
No. of securities held prior to change	178,125 Fully Paid Ordinary Shares 247,000 Unlisted Options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
Class	(a) Fully Paid Ordinary Shares (b) Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 (c) Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023
Number acquired	(a) 35,625 Fully Paid Ordinary Shares (b) 17,813 Listed PTXOC Options (c) 415,000 Unlisted Options

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) \$1,781.25 (b) Nil (c) Nil
No. of securities held after change	213,750 Fully Paid Ordinary Shares 247,000 Unlisted Options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019 17,813 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 415,000 Unlisted Options, exercisable at \$0.0633 (6.63 cents) per option, expiring on 2 May 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Acceptance of entitlements in accordance with the Company's Prospectus dated 25 March 2019. (b) Issued pursuant to the Company's Prospectus dated 25 March 2019 (c) Issue of options pursuant to Resolution 8 as approved by Shareholders at a General Meeting held of shareholders on 26 April 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	6 July 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p>
Date of change	<p>(a) 30 April 2019</p> <p>(b) 30 April 2019</p> <p>(c) 2 May 2019</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	
Paul Edward Alexander Hopper	1,038,137 Fully paid ordinary shares
Deborah Anne Coleman (a related party of Mr Hopper)	2,216,667 Fully paid ordinary shares
Moreglade Pty Ltd (a controlled entity of Mr Hopper)	2,333,334 Fully paid ordinary shares
Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)	3,572,778 Fully paid ordinary shares 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
Class	(a) Fully Paid Ordinary Shares (b) Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents), expiring on 31 March 2023 (c) Unlisted Options, exercisable at \$0.0663 (6.63 cents), expiring on 2 May 2023
Number acquired	(a) 207,628 Fully Paid Ordinary Shares (b) 103,814 Listed PTXOC Options (c) 415,000 Unlisted Options
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) \$10,381.40 (b) Nil (c) Nil
No. of securities held after change	
Paul Edward Alexander Hopper	1,245,765 Fully paid ordinary shares 103,814 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents), expiring on 31 March 2023 415,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents), expiring 2 May 2023
Deborah Anne Coleman (a related party of Mr Hopper)	2,216,667 Fully paid ordinary shares
Moreglade Pty Ltd (a controlled entity of Mr Hopper)	2,333,334 Fully paid ordinary shares
Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)	3,572,778 Fully paid ordinary shares 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Acceptance of entitlements in accordance with the Company's Prospectus dated 25 March 2019. (b) Issued pursuant to the Company's Prospectus dated 25 March 2019. (c) Issue of options pursuant to Resolution 7 as approved by Shareholders at a General Meeting held of shareholders on 26 April 2019.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Engle
Date of last notice	9 November 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	2 May 2019
No. of securities held prior to change	370,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
Class	Unlisted options exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023
Number acquired	670,000
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	370,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019 670,000 Unlisted options exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options pursuant to Resolution 6 as approved by Shareholders at a General Meeting held of shareholders on 26 April 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	19 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> 1. Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) 2. Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) 3. Alexandra Elizabeth Yatomi-Clarke
Date of change	<ol style="list-style-type: none"> (a) 30 April 2019 (b) 30 April 2019 (c) 2 May 2019
No. of securities held prior to change	<p>Direct 2,000,000 Unlisted Options exercisable at \$0.1021 (10.21 cents) per option, expiring 18 December 2022</p> <p>Indirect</p> <ol style="list-style-type: none"> 1. 3,245,000 Fully paid ordinary shares 2. 976,912 Fully paid ordinary shares 3. 172,500 Fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Class	(a) Fully Paid Ordinary Shares (b) Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 (c) Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023
Number acquired	(a) 195,383 Fully Paid Ordinary Shares (b) 97,692 Listed PTXOC Options (c) 3,500,000 Unlisted Options
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) \$9,769.15 (b) Nil (c) Nil
No. of securities held after change	Direct 2,000,000 Unlisted Options exercisable at \$0.1021 (10.21 cents) per option, expiring 18 December 2022 3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023 Indirect 1. 3,245,000 Fully paid ordinary shares 2. 1,172,295 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 3. 172,500 Fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Acceptance of entitlements in accordance with the Company's Prospectus dated 25 March 2019. (b) Issued pursuant to the Company's Prospectus dated 25 March 2019. (c) Issue of options pursuant to Resolution 5 as approved by Shareholders at a General Meeting held of shareholders on 26 April 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.